Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Revenues:        
Royalties $ 3,213 $ 2,431 $ 9,256 $ 6,597
Material sales 1,818 1,679 4,150 5,713
Collaborative research and development and other revenues 1,344 1,631 4,347 4,791
Total revenues 6,375 5,741 17,753 17,101
Operating costs and expenses:        
Cost of sales 683 703 1,273 2,851
Research and development 2,647 2,471 8,315 7,693
General and administrative 4,382 3,962 11,824 11,261
Write-off of in-process research and development    2,282    2,282
Lease exit and termination costs (15) (2) 159 (168)
Total operating costs and expenses 7,697 9,416 21,571 23,919
Accretion of deferred gain on sale leaseback    426    1,277
Loss from operations (1,322) (3,249) (3,818) (5,541)
Other income (expense):        
Interest expense, net (838) (699) (2,460) (1,762)
Decrease (increase) in contingent liabilities 2,093 (198) 1,191 (1,317)
Other, net 15 (10) 272 74
Total other income (expense), net 1,270 (907) (997) (3,005)
Income (loss) before income taxes (52) (4,156) (4,815) (8,546)
Income tax benefit (expense) (142) (22) (445) 13,572
Income (loss) from continuing operations (194) (4,178) (5,260) 5,026
Discontinued operations:        
Income tax benefit on discontinued operations       14   
Discontinued operations       3,670 3
Net income (loss): (194) (4,178) (1,590) 5,029
Basic and diluted per share amounts:        
Income (loss) from continuing operations (in usd per share) $ (0.01) $ (0.21) $ (0.27) $ 0.26
Discontinued operations (in usd per share)       $ 0.19   
Net income (loss) (in usd per share) $ (0.01) $ (0.21) $ (0.08) $ 0.26
Weighted average number of common shares-basic (in shares) 19,917,676 19,673,160 19,791,793 19,648,947
Weighted average number of common shares-diluted (in shares) 19,917,676 19,673,160 19,791,793 19,686,353
AVINZA Product Line
       
Discontinued operations:        
Gain on sale of Product Line, net       3,656   
Oncology Product Line
       
Discontinued operations:        
Gain on sale of Product Line, net          $ 3